Literature DB >> 27328848

Hepatitis C genotype 3 disease.

Sarah Kattakuzhy1, Rachel Levy2, Elana Rosenthal3, Lydia Tang3, Eleanor Wilson3, Shyam Kottilil3.   

Abstract

Hepatitis C genotype 3 (GT-3) infection comprises up to 30 % of all HCV infections worldwide, with roughly 54.3 million cases concentrated in South and Southeast Asia. Longitudinal studies have demonstrated significantly increased rates of steatosis, fibrosis, and hepatocellular carcinoma in GT-3 disease, thus distinguishing this genotype as both the most difficult and urgent to treat. However, novel direct-acting antiviral agents currently approved have not demonstrated the uniform potency seen in GT-1 disease for GT-3. This review outlines (1) the epidemiology and natural history, (2) phase II and III clinical trials demonstrating effective treatment options, and (3) current and future therapeutic issues in the quest to eradicate hepatitis C genotype 3 disease.

Entities:  

Keywords:  Genotype-3; Hepatitis C; Treatment review

Mesh：

Substances：

Year:  2016        PMID： 27328848     DOI： 10.1007/s12072-016-9748-z

Source DB:  PubMed          Journal:  Hepatol Int        ISSN： 1936-0533            Impact factor:   6.047


  38 in total

1.  Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C.

Authors:  Michael Manns; Stefan Zeuzem; Ajit Sood; Yoav Lurie; Markus Cornberg; Hartwig Klinker; Peter Buggisch; Martin Rössle; Holger Hinrichsen; Ismail Merican; Yaron Ilan; Stefan Mauss; Saif Abu-Mouch; Andryes Horban; Thomas H Müller; Christoph Welsch; Rongdean Chen; Rab Faruqi; Lisa D Pedicone; Heiner Wedemeyer
Journal:  J Hepatol       Date:  2011-01-13       Impact factor: 25.083

2.  HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis.

Authors:  G Nkontchou; M Ziol; M Aout; M Lhabadie; Y Baazia; A Mahmoudi; D Roulot; N Ganne-Carrie; V Grando-Lemaire; J-C Trinchet; E Gordien; E Vicaut; I Baghad; M Beaugrand
Journal:  J Viral Hepat       Date:  2011-10       Impact factor: 3.728

Review 3.  Role of hepatitis C virus genotype 3 in liver fibrosis progression--a systematic review and meta-analysis.

Authors:  A Probst; T Dang; M Bochud; M Egger; F Negro; P-Y Bochud
Journal:  J Viral Hepat       Date:  2011-07-01       Impact factor: 3.728

4.  Hepatitis C virus genotype-3a core protein enhances sterol regulatory element-binding protein-1 activity through the phosphoinositide 3-kinase-Akt-2 pathway.

Authors:  Candice Jackel-Cram; Ling Qiao; Zhongua Xiang; Robert Brownlie; Yan Zhou; Lorne Babiuk; Qiang Liu
Journal:  J Gen Virol       Date:  2010-02-03       Impact factor: 3.891

5.  Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection.

Authors:  Mark S Sulkowski; Susanna Naggie; Jacob Lalezari; Walford Jeffrey Fessel; Karam Mounzer; Margaret Shuhart; Anne F Luetkemeyer; David Asmuth; Anuj Gaggar; Liyun Ni; Evguenia Svarovskaia; Diana M Brainard; William T Symonds; G Mani Subramanian; John G McHutchison; Maribel Rodriguez-Torres; Douglas Dieterich
Journal:  JAMA       Date:  2014 Jul 23-30       Impact factor: 56.272

6.  Sofosbuvir for previously untreated chronic hepatitis C infection.

Authors:  Eric Lawitz; Alessandra Mangia; David Wyles; Maribel Rodriguez-Torres; Tarek Hassanein; Stuart C Gordon; Michael Schultz; Mitchell N Davis; Zeid Kayali; K Rajender Reddy; Ira M Jacobson; Kris V Kowdley; Lisa Nyberg; G Mani Subramanian; Robert H Hyland; Sarah Arterburn; Deyuan Jiang; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Aasim M Sheikh; Zobair Younossi; Edward J Gane
Journal:  N Engl J Med       Date:  2013-04-23       Impact factor: 91.245

7.  Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience.

Authors:  Ajit Sood; Vandana Midha; Syed Hissar; Manoj Kumar; Pothakamuri V Suneetha; Manu Bansal; Nina Sood; Puja Sakhuja; Shiv K Sarin
Journal:  J Gastroenterol Hepatol       Date:  2007-07-20       Impact factor: 4.029

8.  Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial.

Authors:  Stephen Pianko; Steven L Flamm; Mitchell L Shiffman; Sonal Kumar; Simone I Strasser; Gregory J Dore; John McNally; Diana M Brainard; Lingling Han; Brian Doehle; Erik Mogalian; John G McHutchison; Mordechai Rabinovitz; William J Towner; Edward J Gane; Catherine A M Stedman; K Rajender Reddy; Stuart K Roberts
Journal:  Ann Intern Med       Date:  2015-11-10       Impact factor: 25.391

9.  Global distribution and prevalence of hepatitis C virus genotypes.

Authors:  Jane P Messina; Isla Humphreys; Abraham Flaxman; Anthony Brown; Graham S Cooke; Oliver G Pybus; Eleanor Barnes
Journal:  Hepatology       Date:  2014-07-28       Impact factor: 17.425

10.  Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.

Authors:  Mark S Sulkowski; David F Gardiner; Maribel Rodriguez-Torres; K Rajender Reddy; Tarek Hassanein; Ira Jacobson; Eric Lawitz; Anna S Lok; Federico Hinestrosa; Paul J Thuluvath; Howard Schwartz; David R Nelson; Gregory T Everson; Timothy Eley; Megan Wind-Rotolo; Shu-Pang Huang; Min Gao; Dennis Hernandez; Fiona McPhee; Diane Sherman; Robert Hindes; William Symonds; Claudio Pasquinelli; Dennis M Grasela
Journal:  N Engl J Med       Date:  2014-01-16       Impact factor: 91.245
View more
  14 in total

1.  Sofosbuvir and velpatasvir: a stellar option for patients with decompensated hepatitis C virus (HCV) cirrhosis.

Authors:  Joel V Chua; Shyam Kottilil
Journal:  Ann Transl Med       Date:  2016-10

Review 2.  Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy.

Authors:  Ameer Abutaleb; Shyam Kottilil; Eleanor Wilson
Journal:  Hepatol Int       Date:  2018-05-29       Impact factor: 6.047

Review 3.  Genotype 3 Infection: The Last Stand of Hepatitis C Virus.

Authors:  Austin Chan; Keyur Patel; Susanna Naggie
Journal:  Drugs       Date:  2017-02       Impact factor: 9.546

4.  Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy.

Authors:  Umberto Restelli; Alfredo Alberti; Adriano Lazzarin; Marzia Bonfanti; Carmela Nappi; Davide Croce
Journal:  Eur J Health Econ       Date:  2016-12-22

5.  Treatment of Chronic Hepatitis C Genotype 3 With Ledipasvir and Sofosbuvir: An Observational Study.

Authors:  Gulzar A Dar; Ghulam N Yattoo; Ghulam M Gulzar; Jaswinder S Sodhi; Suresh Gorka; Mushtaq A Laway
Journal:  J Clin Exp Hepatol       Date:  2020-07-03

Review 6.  Sofosbuvir/velpatasvir: a pangenotypic drug to simplify HCV therapy.

Authors:  Rebecca Lee; Shyam Kottilil; Eleanor Wilson
Journal:  Hepatol Int       Date:  2016-12-07       Impact factor: 9.029

Review 7.  State of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and Immunization.

Authors:  Cecilia Trucchi; Andrea Orsi; Cristiano Alicino; Laura Sticchi; Giancarlo Icardi; Filippo Ansaldi
Journal:  J Immunol Res       Date:  2016-10-24       Impact factor: 4.818

8.  Management of chronic Hepatitis C at a primary health clinic in the high-burden context of Karachi, Pakistan.

Authors:  Yuely A Capileno; Rafael Van den Bergh; Dmytro Donchunk; Sven Gudmund Hinderaker; Saeed Hamid; Rosa Auat; Gul Ghuttai Khalid; Razia Fatima; Aashifa Yaqoob; Catherine Van Overloop
Journal:  PLoS One       Date:  2017-04-27       Impact factor: 3.240

9.  Optimization of direct anti-viral agent treatment schedule: Focus on HCV genotype 3.

Authors:  Filomena Morisco; Rocco Granata; Silvia Camera; Antonio Ippolito; Michele Milella; Fabio Conti; Chiara Masetti; Antonella Smedile; Paolo Tundo; Teresa Santantonio; Maria Rosa Valvano; Antonio Termite; Pietro Gatti; Vincenzo Messina; Angelo Iacobellis; Marta Librandi; Nicola Caporaso; Angelo Andriulli
Journal:  United European Gastroenterol J       Date:  2017-06-20       Impact factor: 4.623

Review 10.  Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.

Authors:  Nader N Massarweh; Hashem B El-Serag
Journal:  Cancer Control       Date:  2017 Jul-Sep       Impact factor: 3.302
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.